Back to results
US 12,758,587 B2Granted
Bone marrow derived CD271 precursor cells for cardiac repair
AssigneeJMHMD Holdings LLC
InventorsJoshua M. Hare, Ian K. McNiece
Life of this patent
Estimating the term…
Abstract
Methods for the isolation of CD271+ stem cell populations are important in the prevention or treatment of cardiovascular diseases and repair of cardiac tissue. The methods are applicable to stem cells from different sources and can be used to treat or prevent diseases or repair of tissues elsewhere in the organism's body.
Claims19
A method of treating ischemic or myocardial tissue damage comprising:
- isolating CD271+ mesenchymal stem cell (MSC) precursors from bone marrow of a subject over a time period of no greater than 5 hours;
- exposing the isolated CD271+ MSC precursors to a demethylation agent, wherein the demethylation agent comprises one or more of 5-aza-2′-deoxycytidine, dimethylsulfoxide, chelerythrine chloride, retinoic acid or salts thereof, 2-amino-4-(ethylthio)butyric acid, procainamide, and procaine, and wherein exposure to the demethylation agent initiates differentiation among the CD271+ MSC precursors into at least one lineage selected from myocardial, vascular, and endothelial lineages;
- parenterally administering to the heart of a patient multiple doses in increasing concentrations of a composition comprising at least one cytokine to form a chemotactic gradient;
- and
- parenterally administering to the patient a therapeutically effective amount of the isolated CD271+ MSC precursors that were exposed to the demethylation agent.
2 more elements
A method of treating ischemic or myocardial tissue damage comprising:
- isolating CD271+ mesenchymal stem cell (MSC) precursors from bone marrow of a subject;
- exposing the isolated CD271+ MSC precursors to a demethylation agent, wherein the demethylation agent comprises one or more of 5-aza-2′-deoxycytidine, dimethylsulfoxide, chelerythrine chloride, retinoic acid or salts thereof, 2-amino-4-(ethylthio)butyric acid, procainamide, and procaine, and wherein exposure to the demethylation agent initiates differentiation among the MSC precursor cells into at least one lineage selected from myocardial, vascular, and endothelial lineages;
- parenterally administering to the heart of a patient multiple doses in increasing concentrations of a composition comprising at least one cytokine to form a chemotactic gradient;
- and
- parenterally administering to the patient a therapeutically effective amount of the isolated CD271+ MSC precursors that were exposed to the demethylation agent;
- wherein the CD271+ MSC precursors are administered as a matrix-cell complex.
3 more elements
Dependencies are inferred from the claim text.